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Abstract
Background: The need for cost effectiveness analyses in randomized controlled trials that compare treatment
options is increasing. The selection of the optimal utility measure is important, and a central question is whether
the two most commonly used indexes - the EuroQuol 5D (EQ5D) and the Short Form 6D (SF6D) – can be used
interchangeably. The aim of the present study was to compare change scores of the EQ5D and SF6D utility indexes
in terms of some important measurement properties. The psychometric properties of the two utility indexes were
compared to a disease-specific instrument, the Oswestry Disability Index (ODI), in the setting of a randomized
controlled trial for degenerative disc disease.
Methods: In a randomized controlled multicentre trial, 172 patients who had experienced low back pain for an
average of 6 years were randomized to either treatment with an intensive back rehabilitation program or surgery to
insert disc prostheses. Patients filled out the ODI, EQ5D, and SF-36 at baseline and two-year follow up. The utility
indexes was compared with respect to measurement error, structural validity, criterion validity, responsiveness, and
interpretability according to the COSMIN taxonomy.
Results: At follow up, 113 patients had change score values for all three instruments. The SF6D had better similarity
with the disease-specific instrument (ODI) regarding sensitivity, specificity, and responsiveness. Measurement error
was lower for the SF6D (0.056) compared to the EQ5D (0.155). The minimal important change score value was
0.031 for SF6D and 0.173 for EQ5D. The minimal detectable change score value at a 95% confidence level were
0.157 for SF6D and 0.429 for EQ5D, and the difference in mean change score values (SD) between them was 0.23
(0.29) and so exceeded the clinical significant change score value for both instruments. Analysis of psychometric
properties indicated that the indexes are unidimensional when considered separately, but that they do not exactly
measure the same underlying construct.
Conclusions: This study indicates that the difference in important measurement properties between EQ5D and SF6D
is too large to consider them interchangeable. Since the similarity with the “gold standard” (the disease-specific
instrument) was quite different, this could indicate that the choice of index should be determined by the diagnosis.
Keywords: Utility measures, Outcome assessment, Measurement properties, Health economics, Low back pain, Lumbar
disc prosthesis, EQ5D, SF6D
* Correspondence: lars.gunnar.johnsen@ntnu.no
†Equal contributors
1Neuroclinic; National Center of spinal disorder, St. Olavs Hospital, Trondheim
University Hospital, Trondheim, Norway
2Clinic of Orthopedics and Rheumatology, Department of Orthopaedic Surgery,
St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
Full list of author information is available at the end of the article
© 2013 Johnsen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Johnsen et al. BMC Musculoskeletal Disorders 2013, 14:148
http://www.biomedcentral.com/1471-2474/14/148
Background
An important way of assessing the effects of treatment in
health economic evaluations is the use of utility indexes.
The outcome scores of general health-related quality of life
(HRQoL) questionnaires are stratified into different health
states [1,2] that can then be validated in a community
population [3,4]. Treatment benefit is thus expressed in a
way that allows health states that are considered less pref-
erable (0) to full health (1) to be given quantitative values.
Because these quantitative values represent a valuation or
preference of health states for the patients, they are called
utility indexes (more utility for the patient with increasing
value). When combined with a follow up period, health
utility indexes are used to calculate quality-adjusted life
years (QALYs). There are several utility indexes that could
be used, and discrepancies exist regarding which index is
most suitable [1,5]. These discrepancies could have impli-
cations for calculating cost-effectiveness when comparing
alternative treatment options for the same disease [6-10].
Two of the most widely used indexes are the EuroQuol 5D
(EQ5D) and the Short Form 6D (SF6D) [4,7].
Two papers assessed the impact that the measure has
on cost-utility estimates [8,9]. Sach et al. found that the
SF6D and EQ5D favored different treatment options for
alleviating knee pain when applying the same cost per
QALY threshold. Søgaard et al. [11] reported on the inter-
changeability of the two indexes. When plotting difference
between change scores of SF6D and EQ5D against their
average in a Bland-Altman plot , they found that the
expected between-measure variation was 0.546 [12]. They
conclude that although both indexes appear to be psycho-
metrically valid for generic assessment of long-lasting back
pain, the variation between them was too great to be con-
sidered interchangeable.
From other studies, we could hypothesize that there
would be a discrepancy between the EQ5D and SF6D
because of differences in valuing similar health states,
evidence of a floor effect in the SF6D and a ceiling effect
in the EQ5D, and because the SF6D can describe severe
health states better than EQ5D [7,13,14].
Further work is required in this field to understand
these discrepancies. Therefore, the aim of this study was
to evaluate change scores values of the EQ5D and SF6D
utility indexes in terms measurement error, structural
validity, criterion validity, responsiveness, and interpret-
ability according to the COSMIN taxonomy. The psy-
chometric properties of the two utility indexes were
compared to a disease-specific instrument, the Oswestry
Disability Index (ODI), in the setting of a randomized
controlled trial for degenerative disc disease.
Methods
Details about the RCT on which this work is based is
reported in detail in Hellum et al. [15]. Between April
2004 and September 2007, 172 patients with diagnosed
chronic low back pain and degenerative disc disease were
randomized to either surgery with total disc replacement
or multidisciplinary rehabilitation. The results from this
study have been published previously [15].
Briefly, data were collected in a multicentre random-
ized controlled trial involving the five university hospi-
tals in Norway. Inclusion criteria included age between
25 and 55 years, LBP for more than a year, degenerative
changes in the intervertebral disc in one of the two low-
est levels of the lumbar spine and an Oswestry Disability
Index score of 30% points or more. Exclusion criteria
included generalized chronic pain syndrome and degen-
eration established in more than two levels. Part of this
study was an economic evaluation of chronic low back
pain treatment. Patients were randomized to either surgery
with insertion of an artificial disc or to non-surgical treat-
ment (a multidisciplinary back rehabilitation program).
The outcomes of patients who completed the SF6D,
EQ5D, and ODI at baseline and at 2-year follow up were
included in this study.
Instruments
ODI
The ODI is a back-specific questionnaire [16,17]. Patients
rate physical disability in activities of daily living due to
low back pain in 10 questions, each of which has verbal
response alternatives. Ratings are summed to yield a score
ranging from 0 (not disabled at all) to 100 (completely
disabled). We used the Norwegian translation of the vali-
dated questionnaire (version 2.0) [18].
SF6D
The SF6D utility index is comprised of 11 items from
the SF-36 [19] that were revised into a six-dimensional
health state classification system. The six dimensions are
physical functioning, role limitations, social functioning,
pain, mental health, and vitality. It reflects a continuous
outcome scored on a 0.29–1.00 scale, with 1.00 indicat-
ing full health [3]. SF6D health states were evaluated
against a normal population using the Standard Gamble
(SG) method. We used the United Kingdom (UK) tariff
[3]. The SF6D was calculated based on the Norwegian
SF-36 (version 2) with the use of syntax files in SPSS 17
(SPSS, New York, US). The syntax files were kindly pro-
vided by Dr J. Brazier, University of Sheffield, UK.
EQ5D
For the EQ5D utility index, responses on a questionnaire
with five dimensions, each comprised of three levels, are
revised into an index with a range from −0.59–1, with
1.00 indicating full health. The 243 possible health states
on the EQ5D are evaluated against a normal population
using the time trade off method (TTO) [20,21]. We used
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the Norwegian version of the EQ5D and syntax files ob-
tained from the EQ5D society using the UK tariff to cal-
culate the index.
Seven-point scale for patient assessment
Many authors suggest a seven-point scale to assess patient
outcome in terms of a global score [22]. On the question:
“How much benefit do you think you have had from the
treatment you have received?” patients answered on a 7-
category response scale that ranged from “I am completely
disabled” to “I am completely recovered”.
Data analysis
We followed the definitions and recommendations from
The COSMIN (COnsensus-based Standards for the selec-
tion of health Measurement INstruments) checklist when
analyzing the psychometric properties of the two utility
indexes and ODI in this study [23].
If not otherwise mentioned, SPSS version 17 was used
in the statistical analysis.
Measurement error
Measurement error concerns the systematic and random
error of a patient`s score that is not attributed to true
changes in the construct to be measured [24]. We used
the standard error of measurement (SEM) to express in-
strument imprecision [22,25-27]. The advantage of using
SEM is that it is considered to be an attribute of the
measure and not a characteristic of the sample itself
[28]. The SEM value could be calculated from a test-
retest study or in a group of stable patients. The SEM in
this study was calculated as:
Sw ¼ SEM ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
2n
∑d2t
r
where sw is the within-subject standard deviation, d is the
difference between two observations in patients i who
reported “unchanged” on a four-point scale between 3 and
6 months follow up and n is the number of subjects [29].
The sw statistics is also called the SEMconsistency [30].
The lowest change that exceeds measurement error
and noise at a 95% confidence level is defined as:
MDC95 ¼ 1:96 
ﬃﬃﬃ
2
p
 SEM ¼ 2:77  SEM
Here, the *
ﬃﬃﬃ
2
p
is introduced because there are two
measurements for each patient. The minimum detectable
change (MDC) at a 95% confidence level, is denoted
MDC95 [31]. With a scale value ≥MDC95, we can be 95%
certain that a change in the measured underlying con-
struct has really occurred [32].
To assess the agreement between EQ5D and SF6D, a
Bland Altman plot was constructed. [12]. The average
EQ5D and SF6D change score values were plotted against
the mean difference in change score values of both instru-
ments. Limits of Agreement (LoA) based on a +/−
1.96*SDdifference interval for the differences were also
constructed.
Structural validity
Structural validity concerns the degree to which the scores
of an instrument are an adequate reflection of the dimen-
sionality of the construct to be measured [33]. Both EQ5D
and SF6D are constructed to measure the dimension of
general health related quality of life (HRQoL) alongside a
continuous scale (from low to high). Using Item Response
Theory (IRT), the unidimensionality of the two utility in-
dexes was tested. The category ordering of the question-
naire items (the probability of moving from an easier to a
harder accomplished category of item answers in parallel
with being increasingly disabled) was also tested.
We employed the unrestricted (Partial-Credit) poly-
tomous model of the Rasch model (for general informa-
tion about fit to the Rasch model, see Additional file 1)
and the test proposed by Smith to reveal unidimension-
ality [34]. The SF6D and EQ5D were tested for unidi-
mensionality in a principal component analysis (PCA)
[35]. We performed a test equating procedure with base-
line values from the SF6D and the EQ5D. The response
of each patient to a question was tested against what
was predicted by the Rasch model. Deviation from the
model is expressed in residuals. Independent t-tests were
used to test if the magnitude of the residuals represents
a significant deviation. The CI calculated for this was
95%. We carried out a binominal test for the proportion
of t-tests outside the range of −1.96–1.96. The software
used in the Rasch analysis was RUMM 2020 (RUMM
Laboratory Pty Ltd.).
Criterion validity
Criterion validity concerns the degree to which the
scores of an instrument are an adequate reflection of a
“gold standard” when this is present [33]. In this analysis
we compared the scores of the EQ5D and SF6D to the
disease specific instrument ODI. The rationale was that
the ODI has been found to be a responsive and valid
measure for patients with LBP [16,18,36] and that an im-
provement assessed by the ODI should be correlated
with an improvement assessed by the two utility indexes.
Spearman rank correlation coefficient (r) with 1000
bootstrap replications of the baseline scores was calcu-
lated to assess the correlation between the scores of the
EQ5D and ODI and SF6D and ODI.
Responsiveness
Responsiveness is defined as the ability of an instrument
to detect change over time in the construct to be mea-
sured [33]. Responsiveness was assessed by using the
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ODI and the seven-point global scores at 2-year follow-
up as “gold standard”. First, we calculated the Spearman
rank correlation coefficient (r) with 1000 bootstrap repli-
cations for the correlation between change scores from
baseline to 2 year FU for the EQ5D, SF6D and ODI. Sec-
ond, we analyzed the area under the Receiver Operator
Curve (ROC) for the change scores of the EQ5D, SF6D
and ODI by using a dichotomization of the patient glo-
bal scores as follows: Categories 1 to 3 was considered
“improved” and categories 4 to 7 were “non-improved”.
Sensitivity was defined as the proportion of patients who
were correctly classified as “improved” and specificity
was defined as the proportion of patients who were cor-
rectly classified as “non-improved”. A receiver operating
characteristic (ROC) curve was then calculated by plot-
ting every possible change score from baseline to 2 year
FU for EQ5D, SF6D and ODI using the global score as
an anchor [37,38]. The area under the ROC curve
(AUC) was then calculated. This value corresponds to
the possibility of correctly diagnosing a patient as having
improved when this is really the case [38] and reflects
how responsive the instruments are to detect a change
in the underlying construct.
The calculation of ROC curves was performed with
MedCalc Statistica software (version 11.1.1. for Win-
dows, Brussels, Belgia).
Interpretability
Interpretability concerns the qualitative meaning of quan-
titative scores or change in scores. A core question is:
“What is the smallest change in score in the construct to
be measured which patients consider important? This is
expressed as the Minimal Important Change (MIC) value
[33], and is calculated based on the sensitivity and specifi-
city results from the ROC analysis described above. The
cut-off value for differentiating between patients with or
without improvement at optimum sensitivity and specifi-
city was determined using ROC analysis [38]. This corre-
sponds to the upper left point on the ROC curve and it
can be interpreted as the point or value that yields the
lowest overall misclassification [25,39].
Study approval
The study was evaluated and approved by the regional
Committee for Medical Research Ethics in east Norway.
Storage of data was allowed by the Norwegian Data In-
spectorate. The study was conducted in accordance with
the Helsinki Declaration and the ICH-GCP guidelines
and registered at clinicaltrial.gov under the identifier
NCT00394732.
Results
At inclusion, there were 52,6% females. Mean age was
41 years and mean (SD) duration of low back pain was 6
years (5,74). Response rates at baseline and 2-year follow
up and pre- and post-treatment scores are presented in
Table 1. At baseline, 133 out of 173 patients had com-
pletely filled out the ODI, the EQ5D, and the SF-36, so
values for each of the instruments could be calculated.
At 2-year follow up, 113 patients had values for all three
instruments, so change scores could be calculated.
Measurement error
The SEM values calculated for patients who were stable
for a period of 3 months are presented in Table 2.
The smallest change score that could be said to repre-
sent a real change beyond measurement error with 95%
probability in one individual (MDC95) are presented in
Table 2.
The proportion of patients with a change score
value ≥MCD95 was 69% for ODI, 57% for SF6D, and 45%
for EQ5D.
Figure 1 shows a Bland-Altman plot of the SF6D and
EQ5D baseline values. It illustrates a systematic variation
(proportional error) in the EQ5D and SF6D scores, with
less healthy individuals tending to have a higher score
on the SF6D and healthier individuals tending to have a
higher score on the EQ5D. The 95% Limits of Agree-
ment (LOA) varied from −0.3 to 0.83 with a mean diffe-
rence in scale scores (SD) of 0.23 (0.29).
Structural validity
When the SF6D items were used as one subset and the
EQ5D items as another, the binominal test showed over-
lap of the 5% expected value with the 95% CI for each of
the indexes. When the EQ5D and SF6D items were com-
bined on a common scale, no overlap was identified. This
finding could indicate that the indexes are unidimensional
Table 1 Response rate at baseline and two year follow up
together with pre- and post-treatment scale scores
Response rate Mean scale score (SD)
Baseline 2 years Baseline 2 year
ODI 99% 100% 42,29 (0,81) 23 (16)
SF6D 82% 90% 0.555 (0,007) 0.692 (0.143)
EQ5D 93% 99% 0.292 (0.026) 0.642 (0.318)
N = 133.
Table 2 SEM and MDC95 values
SEM MDC95
ODI 4.24 11.75
SF6D 0.056 0.157
EQ5D 0.155 0.429
The SEM represents the standard error of measurement. The MDC95 is the
minimal detectable change value that falls outside the measurement error of
the instrument with 95% probability.
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when considered separately, but that they do not exactly
measure the same underlying construct [34,40].
Figures 2 and 3 are graphic representations of the
targeting of the SF6D and EQ5D items. Patients “ability”
(level of health-related quality) and the item location
(moving from an easy to a more difficult category of
item answers in parallel with being increasingly disabled)
are plotted on the same logarithmic scale. The bars in
the top panels represent patient responses, and the bars
in the bottom panels represent item thresholds on the
scales. A threshold is the 0.5 probability point between ad-
jacent item categories [41]. HRQoL levels (i.e., scoring
values) decrease from left to right. Scoring responses out-
side the range of items represent a floor effect (to the right)
or a ceiling effect (to the left). Responses outside the range
of the scale give no additional information, and the test
cannot discriminate between patients who fall in this area.
From Figures 2 and 3 it can be seen that the EQ5D
was relatively well targeted for this group, with no sign
of floor or ceiling effects, i.e., all responders were cap-
tured within the scale. With a mean person-location
value of −0.132, the patients were at a slightly higher
level of HRQoL than the scale could express. No floor
or ceiling effect could be seen in the SF6D, but here the
mean person-location was 1.423. This indicates that
there is a tendency for patients to score at the lower end
of the scale of this index.
Three of the items in the SF6D showed disordered
threshold: question 1: Physical functioning, question 2:
Role limitation and question 4: Pain. A better fit to the
model was achieved if some of the response categories
of these items were omitted. None of the questions in
the EQ5D showed disordered thresholds.
Criterion validity
The correlation between baseline scores of ODI and
EQ5D was r = 0,58 (n = 114, p=0.000) and for ODI and
SF6D: r = 0.38 (n = 114, p = 0.000).
Responsiveness
a) The correlation between change scores of ODI
and EQ5D was r = 0,64 (n = 108, p=0.000) and
between ODI and SF6D change scores: r = 0.77
(n = 108, p = 0.000).
b) Spearman’s rho for the correlation between change
scores of the instruments and global score categories
was 0.84, 0.55 and 0.76 for ODI, EQ5D and SF6D
respectively. The area under the ROC curve, the
possibility of correctly discriminating between
“improved” or “non-improved” patients with a 95%
CI was: 94% (87.5–97.6) for ODI, 90% (82.1–94.6)
for SF6D, and 83% (75–90) for EQ5D. The ROC
curves are presented in Figure 4.
Interpretability
The MIC values defined as the most optimal cut-off
point of change scores plotted on the ROC curve was
for ODI: 12.88,(sensitivity 88%, specificity 85%), EQ5D:
Figure 1 Bland-Altman plot.
Figure 2 Person-item threshold distribution for EQ5D.
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0.173 (sensitivity: 73%, specificity 79%) and SF6D: 0,031
(sensitivity 93%, specificity 78%) (Figure 4).
Discussion
The present study failed to show similarity between
EQ5D and SF6D in several important measurement
properties. EQ5D had a higher value of inherent meas-
urement error than SF6D. The mean difference between
baseline score values had a wide 95% Limits of Agree-
ment in the Bland-Altman plot signifying a low degree
of agreement between the instruments [12,42]. Rasch
analysis showed that although EQ5D and SF6D separ-
ately seem to have unidimensional scale properties they
probably do not measure the same underlying construct.
SF6D show less similarity with the baseline scores of the
disease specific instrument but were more responsive to
detect a change in the underlying construct in addition
to better ability to correctly diagnosing a patient as ha-
ving improved when this was really the case even though
it did not reach the level of the ODI. The MIC values
were quite different and SF6D had a better ability to
identify truly change in scale score beyond measurement
error.
Van Stel et al. showed that the EQ5D and the SF6D
yield dissimilar scores in patients with coronary heart
disease, and consequently, they cannot be used inter-
changeably [43]. This is in line with the Bland-Altman
plot pattern we found in our study and in agreement
with other previously published reports [6,13,43]. Fur-
thermore, we observed that the magnitude of difference
between the two instruments in the Bland-Altman plot
was beyond the MIC for both instruments and therefore
interpreted as clinically significant.
In this study, sensitivity was defined as the proportion
of patients that truly improved (true-positive rate), and
the sensitivity was the proportion of patients that did
not actually improve (true-negative rate). The EQ5D di-
agnosed fewer patients as clinically improved (change
score values beyond MIC). This was also reflected in the
MIC/MDC95 ratio (the proportion of patients who truly
changed with a possibility of 95% predicted by the in-
struments): For the MIC value to reach the MDC95, the
specificity for the SF6D would have to increase from
78.1 to 87.5, but the sensitivity would then fall from 92.5
to 73.7. For the EQ5D, this would necessitate an increase
in specificity from 78.9 to 86.8 and a decrease in sensi-
tivity from 72.8 to 57.6. In other words, to reach a value
beyond the 95% CI for measurement error, the probabil-
ity of correctly classifying a patient as improved would
fall dramatically for the EQ5D, nearly reaching 50% or
classifying by chance. The effect was not as dramatic for
the SF6D, which would still correctly classify over 70%
of patients as “improved”.
We found that the difference in the range of the scales
between the SF6D and the EQ5D could be reflected in
Figure 3 Person-item threshold distribution for SF6D.
0 20 40 60 80 100
100
80
60
40
20
0
100-Specificity
Se
ns
iti
v
ity
Change score ODI
Change score SF6D
Change score EQ5D
Figure 4 ROC curve.
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their targeting properties. Based on the Rasch analysis
(Figures 3 and 4), we could hypothesize that patients
were at a lower level of HRQoL than the SF6D could ex-
press (floor effect). The range of patient abilities was bet-
ter captured within the EQ5D scale. Barton et al. [6]
compared the performance of the EQ5D and the SF6D
in 1865 individuals over ≥45 years old. They found that
healthier individuals had higher scores on the EQ5D,
and less healthy individuals such as patients with back
pain had higher scores on the SF6D. In a study that
compared the SF6D and the EQ5D in liver transplant
patients, Longworth et al. observed that the SF6D does
not describe health states at the lower end of the utility
scale but is more sensitive than the EQ5D in detecting
small changes at the top of the scale [14]. This result is
somewhat confusing because the same group later pub-
lished a paper in which they conclude that the SF6D can
describe some “poor health states including states that
(according to the EQ5D scoring algorithm) are viewed
as worse than the state of being dead” [13].
The Rasch analysis also revealed that some of the
SF6D items did not function as intended. A better fit to
the model was achieved if some of the response categor-
ies of these items were collapsed (i.e., the category was
removed from the item). An interpretation of this is that
for these items, patients could not differentiate between
two adjacent response categories and the information in
the removed categories was therefore redundant. None
of the items in the EQ5D showed similar signs of dys-
function. When treated as separate scales, both instru-
ments showed signs of unidimensionality, but significant
invariance across items was noted when analyzed as one
scale (all items from the SF6D and the EQ5D put to-
gether). The interpretation of this was that the two
scales seem to measure different aspects of HRQoL.
Walters and Brazier mentioned that a fundamental as-
sumption in their comparison of the EQ5D and the
SF6D was that the instruments should measure the same
underlying HRQOL variable [44].
Strengths and limitations of the study
Compared to Brazier et al. [7], SF6D in our study had a
higher percentage of missing data at both assessment
time points (baseline and 2-year follow up). As Brazier
mentioned in another paper, this has important conse-
quences for data quality [45].
The use of global assessment score has been questioned
in several studies [46,47]. Criticism of the reliability of an-
chor based methods includes no standardization of an-
chors, time dependence of patients perception of health,
dependence on only one question and failure of the an-
chor question to differentiate between quantitative and
qualitative perception of change [48]. The COSMIN study
did not reach any consensus about which method to use
to determine the MIC value but conclude that there is an
ongoing discussion about this in the literature [23]. Some
authors now suggest ROC analysis for determining MIC
values mainly because it uses all available data and maxi-
mizes the number of individuals correctly classified [49].
The question and answer categories in our 7-point global
scale was not a standardized scale but Spearman`s rho for
the correlation between change scores of the instruments
and global score categories used in the ROC analysis was
considered acceptable (0.84, 0.55 and 0.76 for ODI, EQ5D
and SF6D respectively) [46,50,51].
Conclusions
EQ5D and SF6D measure different aspects of HRQoL.
The difference in psychometric properties between them
and the lack of agreement is probably clinically significant.
Because the ability to detect a change in the underlying
construct and similarity to a disease-specific instrument is
quite different, the choice of instrument should probably
be guided by diagnosis and/or treatment choice. In our
study of patients with chronic low back pain, the SF6D
had the best ability to detect change and correctly identify
patients as improved or non-improved beyond a 95% con-
fidence level of measurement error.
Finally, our study supports the findings of Soegaard
et al. [11]. They concluded that the SF6D and EQ5D
cannot be used interchangeably for measurement of
preference value and that sensitivity analysis examining
the impact of between-measure discrepancy remains a
necessary condition for cost-utility evaluation results.
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